Synchron

Executive Summary

Synchron is a clinical-stage medical device company developing a minimally invasive brain-computer interface (BCI) platform to restore functional independence for individuals with severe paralysis. Its stent-like device is delivered via an endovascular procedure, avoiding open brain surgery. The company's technology has demonstrated the ability to enable patients to control digital devices with their thoughts, potentially improving quality of life. Currently, Synchron is advancing through clinical trials and seeking FDA approval for its BCI system. The platform's unique endovascular approach could offer a safer, more accessible alternative to traditional BCIs, positioning the company as a leader in the emerging neuromodulation space. With strong intellectual property and early clinical evidence, Synchron is poised for significant milestones in the near future.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval for Early Feasibility Study Expansion80% success
• Q4 2026Interim Clinical Trial Results in Paralysis Patients65% success
• Q3 2026Strategic Partnership or Funding Announcement60% success